Moderna stock dips on 50% RSV vaccine efficacy after 18 months

Well, one more here, Moderna That stock falling after the company said its newly approved RSV vaccine was only about 50% effective after 18 months, you find Angeli Klane following the story.It could still be Well, we're seeing the stock down right now because investors are are looking at the Moderna drug compared to compared to Pfizer and those who also in the market in the same 60 older population.If you take a look at, uh, GSK, they have 60% and Pfizer at 77% over longer periods of time.

But as we know, uh, CEO Stefan Mansell has had his eye on the RSV market for a while, thinking about the broader opportunity.It's bigger than the flu market of the do so, as you can see, you know, looking at that 10 billion as a potential. Departing Nvidia VP salutes Jensen Huang’s leadership, and pinpoints the 3 key principles he taught her

Business Business Latest News, Business Business Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

'50-50 chance' that AI outsmarts humanity, Geoffrey Hinton saysAt a time when the AI boom is pushing tech company valuations into the trillions, the Godfather of AI, Geoffrey Hinton, is urging the industry to set aside vast sums of money to address an existential threat — what happens if AI becomes smarter than...
Source: BNNBloomberg - 🏆 83. / 50 Read more »

Moderna’s RSV Shot Wins FDA Approval for Use in Older AdultsModerna Inc. gained US approval for its RSV vaccine in older adults, giving the biotech a second product as it seeks to move beyond its reliance on the fading Covid-19 market.
Source: BNNBloomberg - 🏆 83. / 50 Read more »